Dr. Andrew Hertler on The FDA Restricting PD-1 Inhibitor Use for PD-L1-Negative Stomach & Esophageal Cancers
Andrew Hertler, MD, Senior Advisor and Chief Medical Officer – emeritus for Evolent, discusses the FDA’s Oncologic Drugs Advisory Committee’s (ODAC) support of the FDA’s decision to restrict the use of PD-1 inhibitor drugs in first-line PD-L1-negative stomach and esophageal cancer. ...
Advertisement
Advertisement
Advertisement

Expert Interviews

Urban Health Weekly

Featured Knowledge Hubs

AI in Medicine

Network Websites

Powered by DocWire News